[Complementary chemotherapy of breast cancer; experience at the University Clinic of Navarra].
From 1982 to 1989, 68 patients were treated with the diagnosis of breast cancer. 57 were premenopausal and 11 postmenopausal. The most frequent stage was T2N1 (44.1%) followed by T1N1 (20.6%). The mean dosage of chemotherapy given were 91.2% for cyclophosphamide, 88% for methotrexate and 94% for 5-fluorouracil. The treatment was well tolerated and the most frequent toxicity encountered was leukopenia. The disease free survival were 89.4% at 96 month for premenopausal and 63.3% at 68 month for postmenopausal. We have not seen any differences in the disease free survival in relation to the size of the tumor or the status of the hormonal receptors of the tumor. The most important prognostic factor were the number of positive axilar nodes affected and the dosage of chemotherapy.
Vieitez
J M
JM
Departamento de Oncología Médica, Clínica Universitaria de Navarra, Pamplona.
Martín Algarra
S
S
Muñoz
L
L
Fernández Hidalgo
O
O
Herranz
P
P
Azinovick
I
I
Zornoza
G
G
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005500:Follow-Up Studies; D006785:Hospitals, University; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009367:Neoplasm Staging; D013030:Spain; D015996:Survival Rate
D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
Quimioterapia complementaria del cáncer de mama; experiencia de la Clínica Universitaria de Navarra.